Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-12-27
2005-12-27
Helms, Larry R. (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S300000, C435S320100, C435S069600
Reexamination Certificate
active
06979730
ABSTRACT:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
REFERENCES:
patent: WO 98/00540 (1998-01-01), None
patent: WO 98/51805 (1998-11-01), None
patent: WO 98/51824 (1998-11-01), None
Overbeek (1994, “Factors affecting transgenic animal production,” Transgenic animal technology, pp. 96-98.
Wall, 1996 Theriogenology, vol. 45, pp. 57-68.
Houdebine, 1994, J. Biotech. vol. 34, pp. 269-287.
Kappell, 1992, Current Opinions in Biotechnology, vol. 3, pp. 548-553.
Cameron, 1997, Molec. Biol. 7, pp. 253-265.
Niemann, 1997, Transg. Res. 7, pp. 73-75.
Mullins (1993, Hypertension, vol. 22, pp. 630-633.
Mullins (1990, Nature, vol. 344, 541-544.
Hammer (1990, Cell, vol. 63, 1099-1112.
Mullins, 1989, EMBO J., vol. 8, pp. 4065-4072.
Taurog, 1988, Jour. Immunol., vol. 141, pp. 4020-4023.
Mullins (1996, J. Clin. Invest. vol. 98, pp. S37-S40.
Reiger et al. (Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976.
Arlen, Myron et al., “Immunotherapy of Colon Cancer Using Chimeric mAb 31.1,”Critical Review in Immunology, 1998,18:133-8. (Exhibit 2).
Arthur, Jill F. et al., “A Comparison of Gene Transfer Methods in Human Dendritic Cells,”Cancer Gene Therapy, 1997,4:17-25. (Exhibit 3).
Ashley, David M. et al., “Bone Marrow-generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors,”Journal of Experimental Medicine, Oct. 6, 1997,186:1177-82. (Exhibit 4).
Bamezai, Anil and Kenneth L. Rock, “Overexpressed Ly-6A.2 Mediates Cell-Cell Adhesion by Binding a Ligand Expressed on Lymphoid Cells,”Proc Nat'l Acad Sci USA, May 1995,92:4294-8. (Exhibit 5).
Brakenhoff, Ruud H. et al., “The Human E48 Antigen, Highly Homologous to the Murine Ly-6 Antigen ThB, is a GPI-anchored Molecule Apparently Involved in Keratinocyte Cell-Cell Adhesion,”Journal of Cell Biology, Jun. 1995,129:1677-89. (Exhibit 6).
Braun, Benjamin S. et al., “Identification of Target Genes for the Ewing's Sarcoma EWS/FLI Fusion Protein by Representational Difference Analysis,”Molecular and Cell Biology, Aug. 1995,15:4623-30. (Exhibit 7).
Cher, Michael L. et al., “Comparative Genomic Hybridization, Allelic Imbalance, and Fluorescence In Situ Hybridization on Chromosome 8 in Prostate Cancer,”Genes, Chromosomes&Cancer, 1994,11:153-62. (Exhibit 8).
Cohen, Stanley N. et al., “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA,”Proc. Nat'l Acad Sci USA, Aug. 1972,69:2110-4. (Exhibit 9).
Cupp, Michael R. and Osterling, Joseph E., “Prostate-Specific Antigen, Digital Rectal Examination and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer,”Mayo Clinic Proceedings, Mar. 1993,68:297-306. (Exhibit 10).
Deleersnijder, Willy et al., “Isolation of Markers for Chondro-osteogenic Differentiation Using cDNA Library Subtraction,”Journal of Biological Chemistry, Aug. 9, 1996,271:19475-82. (Exhibit 11).
Fields, Stanley and Ok-kyu Song, “A Novel Genetic System to Detect Protein-Protein Interactions,”Nature, Jul. 20, 1989,340:245-6. (Exhibit 12).
Fong, Lawrence et al., “Induction of Tissue-Specific Autoimmune Prostatitis with Prostatic Acid Phosphatase Immunization Implications for Immunotherapy of Prostate Cancer,”Journal of Immunology, 1997,159:3113-7. (Exhibit 13).
Foon, Kenneth A. et al., “Immune Response to the Carcinoembryonic Antigen in Patients Treated with an Anti-Idiotype Antibody Vaccine,”Journal of Clinical Investigation, Jul. 1995,96:334-42. (Exhibit 14).
Fritz, Benjamin A. and Anson W. Lowe, “Polarized GP2 Secretion in MDCK Cells Via GPI Targeting and Apical Membrane-Restricted Proteolysis,”American Journal of Physiology, Jan. 1996,270:G176-83. (Exhibit 15).
Funakoshi, Satoshi et al., “Differntial In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and AntiCD20 Monoclonal Antibodies Against Human B-Cell Lymphomas,”Journal of Immunotherapy, 1996,19(2):93-101. (Exhibit 16).
Graham, F. L. and A. J. Van Der Eb, “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,”Virology, 1973,52:456-67. (Exhibit 17).
Liu, He et al., “Constitutive and Antibody-induced Internalization of Prostate-specific Membrane Antigen,”Cancer Research, Sep. 15, 1998,58:4055-60. (Exhibit 18).
Henderson, Robert A. et al., “Human Dendritic Cells Genetically Engineered to Express High Levels of the Human Epithelial Tumor Antigen Mucin (MUC-1),”Cancer Research, Aug. 15, 1996,56:3763-70. (Exhibit 19).
Herlyn, Dorothee et al., “Anti-Idiotype Cancer Vaccines: Past and Future,”Cancer Immunology Immunotherapy, 1996,43:65-76. (Exhibit 20).
Hodge, James W. et al., “A Recombinant Vaccinia Virus Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a Non-Human Primate,”International Journal of Cancer, 1995,63:231-7. (Exhibit 21).
Israeli, Ron S. et al., “Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen,”Cancer Research, Jan. 15, 1993,53:227-30. (Exhibit 22).
Jenkins, Robert B. et al., “Detection of c-myc Oncogene Amplificaiton and Chromosomal Anomalies in Metastatic Prostatic Carcinoma by Fluorescence in Situ Hybridization,”Cancer Research, Feb. 1, 1997,57:524-31. (Exhibit 23).
Kasprzyk, Philip G. et al., “Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies,”Cancer Research, May 15, 1992,52:2771-6. (Exhibit 24).
Katz, Ben-Zion et al., “An Association Between High Ly-6A/E Expression on Tumor Cells and a Highly Malignant Phenotype,”International Journal of Cancer, 1994,59:684-91. (Exhibit 25).
Kieffer, Bruno et al., “Three-Dimensional Solution Structure of the Extracellular Region of the Complement Regulatory Protein CD59, a New Cell-Surface Protein Domain Related to Snake Venom Neurotoxins,”Biochemistry, 1994,33:4471-82. (Exhibit 26).
Klein, Karen A. et al., “Progression of Metastatic Human Prostate Cancer to Androgen Independence in Immunodeficient SCID Mice,”Nature Medicine, Apr. 1997,3:402-8. (Exhibit 27).
Lalani, El-Nasir et al., “Molecular and Cellular Biology of Prostate Cancer,”Cancer and Metastasis Reviews, 1997,16:29-66. (Exhibit 28).
Lee, Cheryl T. and Joseph E. Oesterling, “Cancer of the Prostate: Diagnosis and Staging,”Urologic Oncology, 1997,W. B. Saunders Company, Philadelphia, 357-77. (Exhibit 29).
Magi-Galluzzi, C. et al., “Mitogen-Activated Protein Kinase Phosphatase 1 is Overexpressed in Prostate Cancer and is Inversely Related to Apoptosis,”Laboratory Investigation, Jan. 1997,76:37-51. (Exhibit 30).
Mao Mao et al., “RIG-E,a Human Homolog of the Murine Ly-6 Family, is Induced by Retinoic Acid During the Differentiation of Acute Promyelocytic Leukemia Cell,”Proc Nat'l Acad Sci USA, Jun. 1996,93:5910-4. (Exhibit 31).
Mount, Peter F. et al., “Chimeric (Mouse/Human) Anti-Colon Cancer Antibody c30.6 Inhibits the Growth of Human Colorectal Cancer Xenografts inscid/scidMice,”Cancer Research, Dec. 1, 1994,54:6160-6. (Exhibit 32).
Noda, Satoshi et al., “Protection from Anti-TCR/CD3-induced Apoptosis in Immature Thymocytes by a Signal through Thymic Shared Antigen-1/Stem Cell Antigen-2,”Journal of Experimental Medicine, May 1996,183:2355-60. (Exhibit 33).
Ozaki, Shuji et al., “Immunotherapy of Multiple Myeloma with a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HMI.24,”Blood, Oct. 15, 1997, 90:3179-3186. (Exhibit 34).
Jakobovits Aya
Reiter Robert E.
Saffran Douglas C.
Witte Owen N.
Helms Larry R.
The Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
Nucleic acids encoding prostate stem cell antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding prostate stem cell antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding prostate stem cell antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493352